Mia's Feed
Medical News & Research

Open Source Innovation Boosts Accessibility of Medical Devices for Rare Patient Groups

Open Source Innovation Boosts Accessibility of Medical Devices for Rare Patient Groups

Share this article

The University of Twente pioneers open-source medical devices, like the 3D base plate, enhancing accessibility for small patient groups and promoting innovation in healthcare technology.

2 min read

The University of Twente has launched its first open-source medical device compliant with MDR regulations: the 3D base plate. This initiative offers an alternative pathway to develop low-risk medical devices that often lack commercial viability but still deliver significant clinical benefits.

A prime example is the 3D footplate—a diagnostic imaging tool targeting rearfoot pathologies. Designed to be produced by medical professionals at cost, this device comes with comprehensive MDR documentation available through open-source platforms, enabling easier manufacturing and regulatory compliance.

Within the Biomedical Device Design & Production group at UT (TechMed Center), efforts are underway to facilitate the availability of medical devices as open-source solutions, including necessary documentation under MDR. This approach allows healthcare providers to create devices themselves, reducing costs and administrative burdens. Although the 3D base plate is the university’s first open-source medical device, it certainly won’t be the last.

Developing and launching medical devices typically involves lengthy processes and high costs, compounded by strict regulatory requirements and the need to establish profitable business models. For devices intended for small patient groups or rare diseases, generating sufficient revenue is particularly challenging, often preventing innovative tools from reaching those who could benefit most.

The 3D footplate exemplifies such innovation. It aids in complex hindfoot pathology diagnosis by positioning the foot during CT scans to simulate clinical stress tests, providing quantitative data crucial for clinical decision-making. Its design follows a simplified, assembly-friendly approach using laser-cut parts, 3D printing, and standard components, minimizing production costs.

Most of the required MDR documentation, including risk assessments, evaluation tests, assembly instructions, and technical files, has been prepared using UT templates. This comprehensive package, which includes technical drawings and a bill of materials, is shared via open-source platforms, allowing medical centers to produce and adapt the device at cost and integrate it into their quality management systems.

This initiative marks UT's first open-source medical device, with future plans to develop additional tools under the 'Class I Medical Devices' category. Making these tools openly accessible not only increases healthcare accessibility in the Netherlands but also fosters international collaboration, especially in low- and middle-income countries, ultimately contributing to global health improvements.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Improved Survival in Liver Cancer Patients Using Dual Immunotherapy

A novel dual immunotherapy approach combining nivolumab and ipilimumab has significantly improved survival rates and tumor control in patients with advanced liver cancer, offering new hope for treatment. The success of recent clinical trials has led to global approval, marking a major breakthrough in liver cancer management.

Recent Data Highlights Decline in MMR Vaccination Rates Across the United States

Recent research reveals a significant decline in MMR vaccination rates across U.S. counties since the COVID-19 pandemic, raising concerns over herd immunity and potential measles outbreaks.

Revolutionary Use of Cancer Medications Enhances Stroke Recovery and Reduces Brain Damage

Research from Singapore reveals that repurposing cancer drugs, HDAC inhibitors, can protect neurons, reduce brain damage, and enhance recovery after stroke by modulating immune cell activity in the brain. This innovative approach offers new hope for extending stroke treatment windows and improving outcomes.